IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and support clinical and nonclinical work exploring additional solid-tumor indications and treatment combinations. The collaboration extends beyond the company’s ongoing ovarian-cancer program. IMUNON retains its background intellectual property and ownership of new
0